Search Filters
Advanced Search
SMC ID Date Medicine Submission Type Indication
SMC2915 09/03/2026 pembrolizumab (Keytruda®) Non submission

In combination with pemetrexed and platinum chemotherapy for the first‑line treatment of adults with unresectable non-epithelioid malignant pleural mesothelioma
SMC2878 08/12/2025 amivantamab (Rybrevant) Resubmission

In combination with carboplatin and pemetrexed for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with activating epidermal growth factor receptor (EGFR) Exon 20 insertion mutations
SMC2736 07/07/2025 osimertinib (Tagrisso) Full

In combination with pemetrexed and platinum-based chemotherapy for the first-line treatment of adult patients with advanced non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
SMC2768 10/03/2025 amivantamab (Rybrevant) Non submission

In combination with carboplatin and pemetrexed for the treatment of adult patients with advanced non-small cell lung cancer (NSCLC) with EGFR Exon 19 deletions or Exon 21 L858R substitution mutations after failure of prior therapy including an EGFR tyrosine kinase inhibitor (TKI).
SMC2207 07/10/2019 pembrolizumab (Keytruda) Resubmission

In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.
770/12 08/12/2014 pemetrexed (Alimta) Full monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy.
642/10 11/10/2010 pemetrexed (Alimta) Full Non-small cell lung cancer
531/09 08/02/2010 pemetrexed (Alimta) Resubmission first line treatment of patients with locally advanced or metastatic non-small cell lung cancer
342/07 08/09/2008 pemetrexed (Alimta) Resubmission monotherapy for second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology
342/07 12/02/2007 pemetrexed, 500mg, powder for reconstitution (Alimta) Full Locally advanced or metastatic non-small cell lung cancer.
268/06 08/05/2006 Pemetrexed (Alimta) Non submission Locally advanced or metastatic non-small cell lung cancer after prior chemotherapy
192/05 08/08/2005 Pemetrexed 500mg infusion (Alimta®) Full Chemotherapy-naïve patients with unresectable malignant pleural mesothelioma
Publication due date SMC meeting date Medicine Submission Type Indication
TBC TBC pembrolizumab (Keytruda) Full

In combination with pemetrexed and platinum chemotherapy, is indicated for the first-line treatment of metastatic non-squamous NSCLC in adults whose tumours have no EGFR or ALK positive mutations.